Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research

Author(s): Gabriela Jiménez-Valerio, Oriol Casanovas

Journal Name: Current Drug Targets

Volume 17 , Issue 15 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The mechanisms of tumor growth and progression involve the activation of different processes such as neovascularization and angiogenesis. These processes involve tumoral cells and stromal cells. Hence, inhibiting angiogenesis affects tumor growth and proliferation in patients with different types of cancer. Nevertheless, tumoral cells and stromal components are responsible for the resistance to antiangiogenic therapies. The majority of tumors respond to this type of therapy; however, some tumors may be indifferent to antiangiogenic therapies (intrinsic resistance) and other tumors become resistant during treatment (acquired resistance). Different strategies have been proposed to prevent resistance. Preclinical studies and clinical trials are focused to fight this therapeutic approach in order to prevent or delay tumor resistance to antiangiogenic therapies.

Keywords: Acquired resistance, anti-angiogenic therapy, intrinsic resistance, stromal cells, tumor cells.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [1728 - 1734]
Pages: 7
DOI: 10.2174/1389450117666160301101425
Price: $65

Article Metrics

PDF: 26
PRC: 2